The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.
 
Sarah Elizabeth Fenton
No Relationships to Disclose
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
David James VanderWeele
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bayer; Clovis Oncology; Exelixis; Janssen
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation
 
Alicia K. Morgans
Honoraria - Advanced Accelerator Applications; Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Exelixis; Genentech; Janssen; Janssen; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Exelixis; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Myovant Sciences; Myriad Genetics; Novartis; Sanofi
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Dendreon; Genentech; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi; Telix Pharmaceuticals
 
Phillip Lee Palmbos
Research Funding - Immunomedics; Roche
 
Joshua J Meeks
Honoraria - AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; incyte; Janssen; Merck; Nucleix; Urogen pharma
Consulting or Advisory Role - AstraZeneca; Ferring; Merck
Research Funding - Epizyme; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - NMIBC genetic classifier (Inst); TCGA Classifier (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme
 
James Benning
No Relationships to Disclose
 
Siobhan Kenny
No Relationships to Disclose
 
Brenda K. Martone
No Relationships to Disclose
 
Brittany Szymaniak
Honoraria - American Urological Association; InVitae
Consulting or Advisory Role - Clovis Oncology; UROGPO
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753